W STRATEGIES, LLC for BIOGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Monitored H.R. 3630: Temporary Payroll Tax Cut Continuation Act as it relates to Medicare reimbursement for Part B drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to a regulatory pathway for biosimilars and opposing efforts in the President's Budget to alter that pathway. Education about reforming the Risk Evaluation and Mitigation Strategies provision in the FDA in the FDA Administration and Amendments Act of 2007 with respect to the upcoming Prescription Drug User Fee Act Reauthorization for FY 2013-2017.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.